[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Sickle Cell Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 201 pages | ID: SD627DFAEA2EN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.

Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.

Sickle Cell Diseases Treatment Market is segmented on the basis of disease type, therapy, drug class, distribution channel, and geography.

On the basis of disease type, the global Sickle Cell Diseases Treatment Market treatment is segmented as:
  • Sickle beta thalassemia
  • Sickle haemoglobin C disease
  • Sickle cell anaemia
  • Others
On the basis of therapy, the global Sickle Cell Diseases Treatment Market is segmented as:
  • Bone Marrow Transplant
  • Blood Transfusion
  • Gene Therapy
On the basis of the drug class, the global Sickle Cell Diseases Treatment Market is segmented as:
  • Antibiotics
  • Analgesics
  • Antimetabolite (Hydroxyurea)
  • Others
On the basis of the distribution channel, the global Sickle Cell Diseases Treatment Market is segmented as:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.

Based on the geographical regions, a global Sickle Cell Diseases Treatment Market is segmented into Latin America, Europe, North America, the Middle East and Africa, and Asia Pacific. North America is dominating the sickle cell anaemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in Asia Pacific and African regions is favouring the growth of SCD treatment market. Asia-Pacific is one of the speedy growing markets due to the funding of the various industry players for stem cell research

Some of the sickle cell disease treatment providers are Biogen (U.S.), Gamida Cell (Israel), Genetix Pharmaceuticals Inc. (U.S.), Sangamo Biosciences (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Acceleron Pharma (U.S.), Global Blood Therapeutics Inc. (U.S.), Emmaus Medical, Inc. (U.S.), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (U.S.).

In July 2017, Emmaus Medical Inc. Endari (L-glutamine oral powder) received U.S. FDA approval to treat the patients with age of five years and older having sickle cell disease

In 2016 Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases

REPORT OUTLINE:
  • The report provides granular level information about the market size, regional market share and forecast from 2017-2023
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY

2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET INTRODUCTION

2.1. Global Sickle Cell Disease Treatment Market– Taxonomy
2.2. Global Sickle Cell Disease Treatment Market–Definitions
  2.2.1. Disease Type
  2.2.2. Therapy

3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Sickle Cell Disease Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Sickle Cell Disease Treatment Market– Recent Market Introductions

4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY DISEASES TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Sickle Beta Thalassemia
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Sickle Haemoglobin C Disease
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Sickle Cell Anaemia
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Others
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Bone Marrow Transplant
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Blood Transfusion
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Gene Therapy
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Antibiotics
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Analgesics
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Antimetabolites
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Others
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis

8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospitals
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Others
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis

9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Region, 2017 – 2023

10. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.1.1. Sickle Beta Thalassemia
    10.1.1.2. Sickle Haemoglobin C Disease
    10.1.1.3. Sickle Cell Anaemia
    10.1.1.4. Others
  10.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Bone Marrow Transplant
    10.1.2.2. Blood Transfusion
    10.1.2.3. Gene Therapy
  10.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Antibiotics
    10.1.3.2. Analgesics
    10.1.3.3. Antimetabolite (Hydroxyurea)
    10.1.3.4. Others
  10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Hospitals
    10.1.4.2. Diagnostic Centres
    10.1.4.3. Blood Donation Centres
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. U.S.
    10.1.5.2. Canada
  10.1.6. North America Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023
  10.1.7. North America Sickle Cell Disease Treatment Market Dynamics – Trends

11. EUROPE SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.1.1. Sickle Beta Thalassemia
    11.1.1.2. Sickle Haemoglobin C Disease
    11.1.1.3. Sickle Cell Anaemia
    11.1.1.4. Others
  11.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Bone Marrow Transplant
    11.1.2.2. Blood Transfusion
    11.1.2.3. Gene Therapy
  11.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Antibiotics
    11.1.3.2. Analgesics
    11.1.3.3. Antimetabolite (Hydroxyurea)
    11.1.3.4. Others
  11.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Hospitals
    11.1.4.2. Diagnostic Centres
    11.1.4.3. Blood Donation Centres
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.5.1. Germany
    11.1.5.2. UK
    11.1.5.3. France
    11.1.5.4. Spain
    11.1.5.5. Italy
    11.1.5.6. Russia
    11.1.5.7. Poland
    11.1.5.8. Rest of Europe
  11.1.6. Europe Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023
  11.1.7. Europe Sickle Cell Disease Treatment Market Dynamics – Trends

12. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.1.1. Sickle Beta Thalassemia
    12.1.1.2. Sickle Haemoglobin C Disease
    12.1.1.3. Sickle Cell Anaemia
    12.1.1.4. Others
  12.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Bone Marrow Transplant
    12.1.2.2. Blood Transfusion
    12.1.2.3. Gene Therapy
  12.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Antibiotics
    12.1.3.2. Analgesics
    12.1.3.3. Antimetabolite (Hydroxyurea)
    12.1.3.4. Others
  12.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Hospitals
    12.1.4.2. Diagnostic Centres
    12.1.4.3. Blood Donation Centres
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    12.1.5.1. Japan
    12.1.5.2. China
    12.1.5.3. India
    12.1.5.4. ASEAN
    12.1.5.5. Australia & New Zealand
    12.1.5.6. Rest of Asia-Pacific
  12.1.6. Asia-Pacific Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023
  12.1.7. Asia-Pacific Sickle Cell Disease Treatment Market Dynamics – Trends

13. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.1.1. Sickle Beta Thalassemia
    13.1.1.2. Sickle Haemoglobin C Disease
    13.1.1.3. Sickle Cell Anaemia
    13.1.1.4. Others
  13.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Bone Marrow Transplant
    13.1.2.2. Blood Transfusion
    13.1.2.3. Gene Therapy
  13.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Antibiotics
    13.1.3.2. Analgesics
    13.1.3.3. Antimetabolite (Hydroxyurea)
    13.1.3.4. Others
  13.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Hospitals
    13.1.4.2. Diagnostic Centres
    13.1.4.3. Blood Donation Centres
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.5.1. Brazil
    13.1.5.2. Mexico
    13.1.5.3. Argentina
    13.1.5.4. Venezuela
    13.1.5.5. Rest of Latin America
  13.1.6. Latin America Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023
  13.1.7. Latin America Sickle Cell Disease Treatment Market Dynamics – Trends

14. MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  14.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.1.1. Sickle Beta Thalassemia
    14.1.1.2. Sickle Haemoglobin C Disease
    14.1.1.3. Sickle Cell Anaemia
    14.1.1.4. Others
  14.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.2.1. Bone Marrow Transplant
    14.1.2.2. Blood Transfusion
    14.1.2.3. Gene Therapy
  14.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.3.1. Antibiotics
    14.1.3.2. Analgesics
    14.1.3.3. Antimetabolite (Hydroxyurea)
    14.1.3.4. Others
  14.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    14.1.4.1. Hospitals
    14.1.4.2. Diagnostic Centres
    14.1.4.3. Blood Donation Centres
  14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    14.1.5.1. Gulf Cooperation Council (GCC) Countries
    14.1.5.2. Israel
    14.1.5.3. South Africa
    14.1.5.4. Rest of MEA
  14.1.6. MEA Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023
  14.1.7. MEA Sickle Cell Disease Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Biogen (U.S.)
  15.2.2. Gamida Cell (Israel)
  15.2.3. Genetix Pharmaceuticals Inc. (U.S.)
  15.2.4. Sangamo Biosciences (U.S.)
  15.2.5. Alnylam Pharmaceuticals, Inc. (U.S.)
  15.2.6. Acceleron Pharma (U.S.)
  15.2.7. Global Blood Therapeutics Inc. (U.S.)
  15.2.8. Emmaus Medical, Inc. (U.S.)
  15.2.9. Novartis AG (Switzerland)
  15.2.10. Bristol-Myers Squibb Company (U.S.).

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS


More Publications